Update on Management of Cancer-Related Cachexia

详细信息    查看全文

• 作者：Lindsey J. Anderson ; Eliette D. Albrecht ; Jose M. Garcia
• 关键词：Cancer ; Cachexia ; Quality of life ; Muscle loss ; Body weight ; Nutrition ; Inflammation ; Appetite ; Ghrelin ; Exercise ; Therapy ; Multimodal ; Clinical management
• 刊名：Current Oncology Reports
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：19
• 期：1
• 全文大小：
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1534-6269
• 卷排序：19

文摘

Cachexia is a metabolic syndrome driven by inflammation and characterized by loss of muscle with or without loss of fat mass. In cancer cachexia, the tumor burden and host response induce increased inflammation, decreased anabolic tone, and suppressed appetite leading to the clinical presentation of reduced body weight and quality of life (QOL). There is no approved treatment for cancer cachexia, and commonly used nutritional and anti-inflammatory strategies alone have proven ineffective for management of symptoms. Several other pharmacological agents are currently in development and have shown promise as a clinical strategy in early-phase trials. Recently, it has been proposed that multimodal strategies, with an anabolic focus, initiated early in the disease/treatment progression may provide the most therapeutic potential for symptom management. Here we review the data from recent clinical trials in cancer cachexia including pharmacological, exercise, and nutritional interventions.